As this happened, Evercore ISI downgraded its Caribou Biosciences Inc [CRBU] rating to an In-line from a an Outperform in a research note published on June 03, 2024; the price target was decreased to $3 from $13. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early November with a ‘”a Neutral”‘ rating. Evercore ISI began covering CRBU with “an Outperform” recommendation on October 31, 2023. Truist started covering the stock on July 11, 2023. It rated CRBU as “a Buy”.
Price Performance Review of CRBU
On Tuesday, Caribou Biosciences Inc [NASDAQ:CRBU] saw its stock fall -0.53% to $1.87. Over the last five days, the stock has gained 16.15%. Caribou Biosciences Inc shares have risen nearly 17.61% since the year began. Nevertheless, the stocks have fallen -61.20% over the past one year. While a 52-week high of $8.33 was reached on 01/07/25, a 52-week low of $1.50 was recorded on 01/02/25. SMA at 50 days reached $2.0352, while 200 days put it at $2.4701.
Levels Of Support And Resistance For CRBU Stock
The 24-hour chart illustrates a support level at 1.7867, which if violated will result in even more drops to 1.7033. On the upside, there is a resistance level at 1.9967. A further resistance level may holdings at 2.1233. The Relative Strength Index (RSI) on the 14-day chart is 50.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0712, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.00%. Stochastics %K at 62.31% indicates the stock is a holding.
How much short interest is there in Caribou Biosciences Inc?
A steep rise in short interest was recorded in Caribou Biosciences Inc stocks on 2024-12-13, growing by 2.38 million shares to a total of 9.8 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 7.42 million shares. There was a rise of 24.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 18, 2022 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $22 price target.
